Terms: = Ovarian cancer AND TP63, EEC3, 8626, ENSG00000073282, p73H, p63, Q9H3D4, TP73L, p51, OFC8, KET, RHS, B p51B , B p51A , SHFM4, LMS, p73L AND Clinical Outcome
5 results:
1. TLR5/7-mediated PI3K activation triggers epithelial-mesenchymal transition of ovarian cancer cells through WAVE3-dependent mesothelin or OCT4/SOX2 expression.
Park GB; Kim D
Oncol Rep; 2017 Nov; 38(5):3167-3176. PubMed ID: 28901470
[TBL] [Abstract] [Full Text] [Related]
2. Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative.
Edmondson RJ; Crosbie EJ; Nickkho-Amiry M; Kaufmann A; Stelloo E; Nijman HW; Leary A; Auguste A; Mileshkin L; Pollock P; MacKay HJ; Powell ME; Bosse T; Creutzberg CL; Kitchener HC
Gynecol Oncol; 2017 Aug; 146(2):327-333. PubMed ID: 28511869
[TBL] [Abstract] [Full Text] [Related]
3. Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma.
Trinh XB; Tjalma WA; Dirix LY; Vermeulen PB; Peeters DJ; Bachvarov D; Plante M; Berns EM; Helleman J; Van Laere SJ; van Dam PA
PLoS One; 2011; 6(7):e22469. PubMed ID: 21799864
[TBL] [Abstract] [Full Text] [Related]
4. DeltaNp63 expression is associated with poor survival in ovarian cancer.
Marchini S; Marabese M; Marrazzo E; Mariani P; Cattaneo D; Fossati R; Compagnoni A; Fruscio R; Lissoni AA; Broggini M
Ann Oncol; 2008 Mar; 19(3):501-7. PubMed ID: 17998283
[TBL] [Abstract] [Full Text] [Related]
5. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy.
Giuntoli RL; Metzinger DS; DiMarco CS; Cha SS; Sloan JA; Keeney GL; Gostout BS
Gynecol Oncol; 2003 Jun; 89(3):460-9. PubMed ID: 12798712
[TBL] [Abstract] [Full Text] [Related]